

Dationt's Name

## Wilate

## **CareFirst Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Data

rauent s Name:		Date
Patient's ID:		Patient's Date of Birth:
Physician's Name:		
Specialty:		NPI#:
Physician Office Telephone:		Physician Office Fax:
Referring Provider Info: 🗆 Same as Re	questing Provider	
Name:		NPI#:
Fax:		Phone:
Dandaring Provider Info:   Some as De	eferring Provider 🗆	Same as Requesting Provider
Kendering i Tovider Into.   Same as Ke	aciinig i i o viuci 🕳	
<del></del>	_	
Name:Fax:	to dosing limits in a	NPI#:
Name: Fax: Approvals may be subject accepted comp	to dosing limits in a	NPI#:
Name:Fax:	to dosing limits in dendia, and/or evide	NPI#:
Name: Fax:  Approvals may be subject accepted comp  Required Demographic Information:	to dosing limits in opendia, and/or eviden	NPI#:
Name: Fax:  Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:	to dosing limits in opendia, and/or evidendia, and/or evidended	NPI#:
Name: Fax:  Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:  Patient Height:	to dosing limits in opendia, and/or evided  kg  cm  requested drug:	NPI#:

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Hemo - Wilate SGM 1952-A - 04/2025.

Criteria Questions:
1. What is the diagnosis?
□ von Willebrand disease (VWD), Continue to 2
☐ Acquired von Willebrand syndrome (AVWS), Continue to 2
☐ Hemophilia A, <i>Continue to 2</i>
☐ Other, please specify, Continue to 2
<ul> <li>2. Will the requested medication be prescribed by or in consultation with a hematologist?</li> <li>☐ Yes, <i>Continue to 3</i></li> <li>☐ No, <i>Continue to 3</i></li> </ul>
3. Is the request for continuation of therapy?  ☐ Yes, Continue to 13 ☐ No, Continue to 4
4. What is the diagnosis?
□ von Willebrand disease (VWD), <i>Continue to 5</i>
☐ Acquired von Willebrand syndrome (AVWS), No further questions
☐ Hemophilia A, Continue to 9
5 What town of your Willaham delicated days the matient house?
5. What type of von Willebrand disease does the patient have?
☐ Type 1, Continue to 6 ☐ Type 2A, Continue to 6
☐ Type 2B, No further questions
•••
☐ Type 2M, Continue to 6 ☐ Type 2N, Continue to 6
**
☐ Type 3, No further questions ☐ Other, please specify, No further questions
Other, please specify
6. Has the patient had an insufficient response to desmopressin?
Yes, No Further Questions
□ No, Continue to 7
<ul> <li>7. Is there a clinical reason for not trying desmopressin first?</li> <li>☐ Yes, Continue to 8</li> <li>☐ No, Continue to 8</li> </ul>
8. What is the reason? Please document the clinical reason for not trying desmopressin first.
☐ Age less than 2 years, <i>No further questions</i>
☐ Pregnancy, No further questions
☐ Fluid/electrolyte imbalance, <i>No further questions</i>
☐ High risk for cardiovascular or cerebrovascular disease (especially elderly), <i>No further questions</i>
☐ Predisposition to thrombus formation, <i>No further questions</i>
☐ Trauma requiring surgery, No further questions
☐ Life-threatening bleed, <i>No further questions</i>
☐ Contraindication or intolerance to desmopressin, <i>No further questions</i>
☐ Severe type 1 von Willebrand disease, <i>No further questions</i>

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Hemo - Wilate SGM 1952-A - 04/2025.

CVS Caremark Specialty Pharmacy

• 2211 Sanders Road NBT-6

• Northbrook, IL 60062

Phone: 1-888-877-0518

• Fax: 1-855-330-1720

• www.caremark.com

☐ Stimate Nasal Spray is unavailable due to backorder/shortage issues (where a ☐ Other, please specify	applicable), No further questions
9. What is the patient's baseline factor VIII assay level (% activity)?	
☐ Less than 1% to 5% (moderate or severe disease), <i>No further questions</i>	
☐ Greater than 5% (mild disease), <i>Continue to 10</i>	
<ul> <li>10. Has the patient had an insufficient response to desmopressin?</li> <li>☐ Yes, No Further Questions</li> <li>☐ No, Continue to 11</li> </ul>	
11. Is there a clinical reason for not trying desmopressin first?  ☐ Yes, Continue to 12	
□ No, Continue to 12	
12. What is the reason? Please indicate the clinical reason for not trying desmor	oressin first
☐ Age less than 2 years, <i>No further questions</i>	57 C 3 S 111 S C
☐ Pregnancy, No further questions	
☐ Fluid/electrolyte imbalance, <i>No further questions</i>	
☐ High risk for cardiovascular or cerebrovascular disease (especially elderly),	No further questions
☐ Predisposition to thrombus formation, <i>No further questions</i>	
☐ Trauma requiring surgery, <i>No further questions</i>	
☐ Life-threatening bleed, <i>No further questions</i>	
☐ Contraindication or intolerance to desmopressin, <i>No further questions</i>	
☐ Severe type 1 von Willebrand disease, <i>No further questions</i>	
☐ Stimate Nasal Spray is unavailable due to backorder/shortage issues (where a	applicable). No further questions
☐ Other, please specify, No further questions	Tr
13. Is the patient experiencing benefit from therapy (e.g., reduced frequency or ☐ Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>	severity of bleeds)?
attest that this information is accurate and true, and that document information is available for review if requested by CVS Caremark or	
,	
RPrescriber or Authorized Signature	Date (mm/dd/yy)